N-propylglycine hydrochloride | 6939-13-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-propylglycine hydrochloride
• 英文别名: 2-(propylamino)acetic acid hydrochloride；2-(propylamino)acetic acid;hydrochloride
• CAS: 6939-13-5
• 化学式: C₅H₁₁NO₂*ClH
• mdl: MFCD12912942
• 分子量: 153.609
• InChiKey: MCLMPPQSHGLURZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.31
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-propylglycine hydrochloride 、 氯甲酸苄酯 在 sodium hydroxide 、 盐酸 作用下， 以 水 、 甲苯 为溶剂， 反应 4.0h， 以84%的产率得到N-benzyloxycarbonyl-N-(n-propyl)glycine
  参考文献：
  名称：

  Polypeptoids from N-Substituted Glycine N-Carboxyanhydrides: Hydrophilic, Hydrophobic, and Amphiphilic Polymers with Poisson Distribution

  摘要：

  Preparation of defined and functional polymers has been one of the hottest topics in polymer science and drug delivery in the recent decade. Also, research on (bio)degradable polymers gains more and more interest, in particular at the interface of these two disciplines. However, in the majority of cases, combination of definition, functionality and degradability, is problematic. Here we present the preparation and characterization (MALDI-ToF MS, NMR, GPC) of nonionic hydrophilic, hydrophobic, and amphiphilic N-substituted polyglycines (polypeptoids), which are expected to be main-chain degradable and are able to disperse a hydrophobic model compound in aqueous media. Polymerization kinetics suggest that the polymerization is well controlled with strictly linear pseudo first-order kinetic plots to high monomer consumption. Moreover, molar mass distributions of products are Poisson-type and molar mass can be controlled by the monomer to initiator ratio. The presented polymer platform is nonionic, backbone degradable, and synthetically highly flexible and may therefore be valuable for a broad range of applications, in particular as a biomaterial.

  DOI：

  10.1021/ma201015y
• 作为产物：
  描述：

  (R)-(Carboxymethyl-formyl-amino)-phenyl-acetic acid 在 盐酸 作用下， 反应 5.0h， 以93%的产率得到N-propylglycine hydrochloride
  参考文献：
  名称：

  Kihlberg, Jan; Bergman, Rolf; Wickberg, Boerje, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1983, vol. 37, # 10, p. 911 - 916

  摘要：

  DOI：

文献信息

• Pro-drug Compounds
  申请人：Proximagen Limited

  公开号：US20140011773A1

  公开（公告）日：2014-01-09

  A compound of formula (I), or a pharmaceutically acceptable salt thereof: The compound is used in pharmaceutical compositions and in a method of treatment of a disease or medical condition which benefits from inhibition of gap junction activity by administering to a subject suffering from such disease or condition.

  公式(I)的化合物，或其药用可接受盐： 该化合物用于药物组合物中，以及在通过向患有此类疾病或病症的受试者给药来抑制缝隙连接活性的治疗方法中发挥作用。
• [EN] PRODRUGS OF 17β-HSD1 -INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE 17Β-HSD1
  申请人：FORENDO PHARMA LTD

  公开号：WO2016102775A1

  公开（公告）日：2016-06-30

  The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration.

  本发明提供了式（I）的新化合物，其中R1、R2、R3和R4如权利要求中所定义。该发明还涉及它们在治疗或预防类固醇激素依赖性疾病或紊乱方面的应用，例如需要抑制17β-HSD1酶或需要降低内源性雌二醇浓度的类固醇激素依赖性疾病或紊乱。
• [EN] PRO-DRUG COMPOUNDS<br/>[FR] COMPOSÉS PROMÉDICAMENTS
  申请人：PROXIMAGEN LTD

  公开号：WO2014006407A1

  公开（公告）日：2014-01-09

  A compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein Z1, Z2, and Z3, Q, R2, A, and R1 are as defined in the claims.

  翻译结果为：公式(I)的化合物，或其药用可接受的盐；其中Z1、Z2和Z3、Q、R2、A和R1如权利要求中所定义。
• Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents
  申请人：Dyck E. Lillian

  公开号：US20050159393A1

  公开（公告）日：2005-07-21

  Novel compounds of the formula I are described: wherein: R 1 =(CH 2 ) m CH 3 where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, R 2 =H, CH 3 or CH 2 CH 3 R 3 =H or CH 3 R 4 =H or CH 3 R 5 =lower alkyl having from 1 to 5 carbon atoms n is an integer in the range from 1 to 3, and X is carboxyl (COOH) or carbalkoxy (COOR 5 ), cyano (C≡N), phosphonic acid (PO 3 H 2 ), phosphonate ester (PO 3 [R 5 ] 2 ) or 5-tetrazole, and pharmaceutically acceptable salts thereof. Preferably, the compounds are optically pure enantiomers of the R- or S-configuration in which R 3 =R 4 =R 5 =H, R 2 =CH 3 and R 1 is a saturated aliphatic chain of one to five carbon atoms. The compounds are useful as cellular rescue agents.

  描述了公式I的新化合物：其中：R1=(CH2)mCH3，其中m为0或在1到16范围内的整数，或者为具有2到17个碳原子的烯基、炔基、烷氧基、烷基硫醚或烷基亚砜基团，R2=H、CH3或CH2CH3，R3=H或CH3，R4=H或CH3，R5=具有1到5个碳原子的低碳基，n为1到3范围内的整数，X为羧基（COOH）或羧酰氧基（COOR5）、氰基（C≡N）、膦酸（PO3H2）、膦酸酯（PO3[R5]2）或5-四唑，并且其药学上可接受的盐。优选，这些化合物是R-或S-构型的光学纯对映体，其中R3=R4=R5=H，R2=CH3，R1是由一到五个碳原子组成的饱和脂肪链。这些化合物可用作细胞救助剂。
• Structure&amp;ndash;Activity Relationships (SAR) of [&lt;small&gt;D&lt;/small&gt;-Arg&lt;sup&gt;2&lt;/sup&gt;]Dermorphin(1&amp;mdash;4) Analogues, &lt;i&gt;N&lt;sup&gt;&amp;alpha;&lt;/sup&gt;&lt;/i&gt;-Amidino-Tyr-&lt;small&gt;D&lt;/small&gt;-Arg-Phe-X
  作者：Tadashi Ogawa、Tetsuhisa Miyamae、Toru Okayama、Masaki Hagiwara、Shinobu Sakurada、Tadanori Morikawa

  DOI：10.1248/cpb.50.771

  日期：——

  preferable for expression of potent analgesic activity, and that the free carboxyl group is superior in its analgesic activity to that of the esterified or amidated carboxy group at the C-terminal. In addition, N-methylation of the amide bond at the 4th position contributed to improved analgesic activity. These results indicated that the strong and long-lasting analgesic effect of ADAMB is expressed by

  在研究口服给药后具有有效止痛作用的化合物的开发过程中，基于Nα-ami基-甲酰胺的结构，有74个C端类似物（Nα-d基-Tyr-D-Arg-Phe-X）。合成了Tyr-D-Arg-Phe-MeβAla-OH（ADAMB）。在皮下和口服给药后，通过鼠尾压力测试评估它们的镇痛活性，并详细检查其结构活性关系（SAR）。结果清楚地表明，对于有效的镇痛活性，优选在X位上​​含有侧链β-氨基酸的化合物，并且，游离羧基的镇痛活性优于酯化或酰胺化的羧基。 C端。此外，在第4位的酰胺键的N-甲基化有助于改善止痛活性。这些结果表明，ADAMB的强而持久的镇痛作用由Nα-酰胺化，酰胺键在第4位的N-甲基化和碳链长度（β-Ala）的协同作用来表达。残基在第4位，这是最合适的结构。